$Intuitive Surgical(ISRG)$ Int-To The Moon - Tiger Brokers Online Investing Community - To The Moon

$Intuitive Surgical(ISRG)$

Intuitive Surgical Inc.: Poised for a Breakout Ahead of Q3 2025 Earnings:

: Intuitive Surgical Inc. , $ISRG a leader in AI-driven robotic surgical systems, is approaching a potential breakout as it nears its Q3 2025 earnings report on October 21, 2025.

Recent FDA approvals for the da Vinci 5 software and clearance for the Ion endoluminal system trials in the U.S. and Europe have expanded its addressable market, enhancing growth prospects.

These developments enable broader adoption of its robotic systems, particularly for remote surgeries, and diversify revenue streams.

The stock, currently trading at 70% of its 52-week high, offers an attractive risk-to-reward ratio. Congressional insider buying, including Markwayne Mullin’s $100,000 purchase at $443.99 per share and Ro Khanna’s $15,000 at $466.66 in September 2025, signals optimism, possibly tied to anticipated regulatory advancements.

The stock’s P/E ratio of 59.9x, compared to the medical instruments industry’s 26.3x, reflects a premium valuation driven by high market expectations. Analysts set a consensus price target of $589.43, implying a 37.2% upside. Recent earnings of $2.19 per share beat consensus estimates of $1.93 by 13%.

With the healthcare sector, tracked by the Healthcare Select Sector SPDR Fund (XLV), underperforming the S&P 500 by 22% over the past year, a sector recovery could amplify ISRG’s rally, making it a compelling investment opportunity.

@Tiger_comments @TigerStars @Tiger_Newspress @TigerCommunity @TigerWire @Daily_Discussion @TigerEvents

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":489510597447800,"tweetId":"489510597447800","gmtCreate":1760532804357,"gmtModify":1760535249762,"author":{"id":4184660311217232,"idStr":"4184660311217232","authorId":4184660311217232,"authorIdStr":"4184660311217232","name":"Gehlot","avatar":"https://community-static.tradeup.com/news/53dc63242823ec77ec80ac52b1cdf5e2","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"currentWearingBadge":{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.10.29","individualDisplayEnabled":0},"individualDisplayBadges":[{"badgeId":"9427a906234c4b18a82ec3d7730b7fa8-1","templateUuid":"9427a906234c4b18a82ec3d7730b7fa8","name":"Star Contributor","description":"Published at least 3 PICK posts (or 10 IDEA posts) and, within the past 30 days, posted at least 1 PICK post (or 4 IDEA posts) and 1 comment","bigImgUrl":"https://community-static.tradeup.com/news/1866dcf97a73be1c330f85862546aedc","smallImgUrl":"https://community-static.tradeup.com/news/4f5c5fa8e2c7683bb5a7fce8753ee456","redirectLinkEnabled":1,"redirectLink":"https://ttm.financial/activity/market/2023/star-contributors/","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.11.13","individualDisplayEnabled":1,"backgroundColor":{"dark":"#675a37","tint":"#f9ebc2"},"fontColor":{"dark":"#ffffff","tint":"#ab7a0e"}}],"fanSize":142,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/ISRG\">$Intuitive Surgical(ISRG)$</a>&nbsp;</p>\n<p>Intuitive Surgical Inc.: Poised for a Breakout Ahead of Q3 2025 Earnings:</p>\n<p>: Intuitive Surgical Inc. , $ISRG&nbsp;a leader in AI-driven robotic surgical systems, is approaching a potential breakout as it nears its Q3 2025 earnings report on October 21, 2025.&nbsp;</p>\n<p>Recent FDA approvals for the da Vinci 5 software and clearance for the Ion endoluminal system trials in the U.S. and Europe have expanded its addressable market, enhancing growth prospects.&nbsp;</p>\n<p>These developments enable broader adoption of its robotic systems, particularly for remote surgeries, and diversify revenue streams.&nbsp;</p>\n<p>The stock, currently trading at 70% of its 52-week high, offers an attractive risk-to-reward ratio. Congressional insider buying, including Markwayne Mullin’s $100,000 purchase at $443.99 per share and Ro Khanna’s $15,000 at $466.66 in September 2025, signals optimism, possibly tied to anticipated regulatory advancements.</p>\n<p>The stock’s P/E ratio of 59.9x, compared to the medical instruments industry’s 26.3x, reflects a premium valuation driven by high market expectations. Analysts set a consensus price target of $589.43, implying a 37.2% upside. Recent earnings of $2.19 per share beat consensus estimates of $1.93 by 13%.</p>\n<p>With the healthcare sector, tracked by the Healthcare Select Sector SPDR Fund (XLV), underperforming the S&amp;P 500 by 22% over the past year, a sector recovery could amplify ISRG’s rally, making it a compelling investment opportunity.</p>\n<p><a href=\"https://ttm.financial/U/3501196737273098\">@Tiger_comments</a> <a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars</a> <a href=\"https://ttm.financial/U/3527667628464496\">@Tiger_Newspress</a> <a href=\"https://ttm.financial/U/4139029059434852\">@TigerCommunity</a> <a href=\"https://ttm.financial/U/3527667670347831\">@TigerWire</a> <a href=\"https://ttm.financial/U/3527667621665671\">@Daily_Discussion</a> <a href=\"https://ttm.financial/U/3527667667103859\">@TigerEvents</a>&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/ISRG\">$Intuitive Surgical(ISRG)$</a>&nbsp;</p>\n<p>Intuitive Surgical Inc.: Poised for a Breakout Ahead of Q3 2025 Earnings:</p>\n<p>: Intuitive Surgical Inc. , $ISRG&nbsp;a leader in AI-driven robotic surgical systems, is approaching a potential breakout as it nears its Q3 2025 earnings report on October 21, 2025.&nbsp;</p>\n<p>Recent FDA approvals for the da Vinci 5 software and clearance for the Ion endoluminal system trials in the U.S. and Europe have expanded its addressable market, enhancing growth prospects.&nbsp;</p>\n<p>These developments enable broader adoption of its robotic systems, particularly for remote surgeries, and diversify revenue streams.&nbsp;</p>\n<p>The stock, currently trading at 70% of its 52-week high, offers an attractive risk-to-reward ratio. Congressional insider buying, including Markwayne Mullin’s $100,000 purchase at $443.99 per share and Ro Khanna’s $15,000 at $466.66 in September 2025, signals optimism, possibly tied to anticipated regulatory advancements.</p>\n<p>The stock’s P/E ratio of 59.9x, compared to the medical instruments industry’s 26.3x, reflects a premium valuation driven by high market expectations. Analysts set a consensus price target of $589.43, implying a 37.2% upside. Recent earnings of $2.19 per share beat consensus estimates of $1.93 by 13%.</p>\n<p>With the healthcare sector, tracked by the Healthcare Select Sector SPDR Fund (XLV), underperforming the S&amp;P 500 by 22% over the past year, a sector recovery could amplify ISRG’s rally, making it a compelling investment opportunity.</p>\n<p><a href=\"https://ttm.financial/U/3501196737273098\">@Tiger_comments</a> <a href=\"https://ttm.financial/U/9000000000000149\">@TigerStars</a> <a href=\"https://ttm.financial/U/3527667628464496\">@Tiger_Newspress</a> <a href=\"https://ttm.financial/U/4139029059434852\">@TigerCommunity</a> <a href=\"https://ttm.financial/U/3527667670347831\">@TigerWire</a> <a href=\"https://ttm.financial/U/3527667621665671\">@Daily_Discussion</a> <a href=\"https://ttm.financial/U/3527667667103859\">@TigerEvents</a>&nbsp;</p></body></html>","text":"$Intuitive Surgical(ISRG)$ Intuitive Surgical Inc.: Poised for a Breakout Ahead of Q3 2025 Earnings: : Intuitive Surgical Inc. , $ISRG a leader in AI-driven robotic surgical systems, is approaching a potential breakout as it nears its Q3 2025 earnings report on October 21, 2025. Recent FDA approvals for the da Vinci 5 software and clearance for the Ion endoluminal system trials in the U.S. and Europe have expanded its addressable market, enhancing growth prospects. These developments enable broader adoption of its robotic systems, particularly for remote surgeries, and diversify revenue streams. The stock, currently trading at 70% of its 52-week high, offers an attractive risk-to-reward ratio. Congressional insider buying, including Markwayne Mullin’s $100,000 purchase at $443.99 per share and Ro Khanna’s $15,000 at $466.66 in September 2025, signals optimism, possibly tied to anticipated regulatory advancements. The stock’s P/E ratio of 59.9x, compared to the medical instruments industry’s 26.3x, reflects a premium valuation driven by high market expectations. Analysts set a consensus price target of $589.43, implying a 37.2% upside. Recent earnings of $2.19 per share beat consensus estimates of $1.93 by 13%. With the healthcare sector, tracked by the Healthcare Select Sector SPDR Fund (XLV), underperforming the S&P 500 by 22% over the past year, a sector recovery could amplify ISRG’s rally, making it a compelling investment opportunity. @Tiger_comments @TigerStars @Tiger_Newspress @TigerCommunity @TigerWire @Daily_Discussion @TigerEvents","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/489510597447800","repostId":0,"isVote":1,"tweetType":1,"viewCount":792,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["ISRG"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1341,"optionInvolvedFlag":true,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/489510597447800"}